e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reducing loss to follow-up during treatment for drug-resistant tuberculosis
Ibrahim Abubakar, Marc Lipman
Source:
Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018
Journal Issue:
January
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ibrahim Abubakar, Marc Lipman. Reducing loss to follow-up during treatment for drug-resistant tuberculosis. Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients
Source: Eur Respir J, 54 (1) 1800353; 10.1183/13993003.00353-2018
Year: 2019
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 41: 1393-1400
Year: 2013
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Long-term results of multidrug-resistant tuberculosis treatment.
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study
Source: Eur Respir J 2006; 28: 980-985
Year: 2006
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018
Year: 2018
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation
Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB)
Year: 2006
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Source: Eur Respir J 2015; 45: 1498-1501
Year: 2015
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001
A new era for treatment of drug-resistant tuberculosis
Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018
Year: 2018
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept